Aclaris Therapeutics (ACRS)
(Real Time Quote from BATS)
$1.19 USD
-0.03 (-2.46%)
Updated Apr 24, 2024 12:52 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ACRS 1.19 -0.03(-2.46%)
Will ACRS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACRS
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aclaris (ACRS) Upgraded to Buy: Here's Why
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Other News for ACRS
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
Commit To Purchase Aclaris Therapeutics At $0.50, Earn 23.4% Annualized Using Options
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)